[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 30 of about 30
1. Li AJ, Zhou WP, Wu MC, Luo XJ: Hepatectomy after primary repair of ruptured liver cancer. Hepatobiliary Pancreat Dis Int; 2007 Jun;6(3):267-70
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Spontaneous rupture of liver tumor is often considered a potentially life-threatening situation.
  • The tumor was in the right hepatic lobe in 2 patients, middle lobe in 1, left median lobe (segment IV) in 1, and caudate lobe (segment I) in 1.
  • Operative methods included right hemihepatectomy in 2 patients, left partial lobectomy or wedge resection in 1, caudate lobe resection in 1, and middle lobctomy+cholecystectomy+abdominal implant resection in 1.
  • Intra-abdominal chemotherapy was given to all 5 patients.
  • Follow-up showed that one patient died from intrahepatic metastasis and hepatic failure six months after re-operation and that two patients died from extensive intra-abdominal metastases six months later.
  • Apart from removing the primary foci, it is necessary to clear abdominal metastatic foci, irrigate the abdomen and administer chemotherapy to prolong the patient's life.

  • Genetic Alliance. consumer health - Liver cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17548249.001).
  • [ISSN] 1499-3872
  • [Journal-full-title] Hepatobiliary & pancreatic diseases international : HBPD INT
  • [ISO-abbreviation] HBPD INT
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


2. Kizaka-Kondoh S, Itasaka S, Zeng L, Tanaka S, Zhao T, Takahashi Y, Shibuya K, Hirota K, Semenza GL, Hiraoka M: Selective killing of hypoxia-inducible factor-1-active cells improves survival in a mouse model of invasive and metastatic pancreatic cancer. Clin Cancer Res; 2009 May 15;15(10):3433-41
Hazardous Substances Data Bank. OXYGEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Selective killing of hypoxia-inducible factor-1-active cells improves survival in a mouse model of invasive and metastatic pancreatic cancer.
  • PURPOSE: Pancreatic cancer is characterized by intratumoral hypoxia, early and aggressive local invasion, and metastatic potential.
  • Hypoxia-inducible factor-1 (HIF-1) is the major transcriptional activator of hypoxia-responsive genes and intratumoral hypoxia is associated with increased risk of metastasis.
  • However, the behavior of the cells having HIF-1 activity during the malignant progression in pancreatic cancer has not been tested.
  • RESULTS: In vivo optical imaging showed that HIF-1 activity proceeded along with local invasion, the peritoneal dissemination, and the liver metastasis.
  • Moreover, selective killing of HIF-1-active hypoxic cells significantly suppressed malignant progression, resulting in a significant improvement in survival rate.
  • CONCLUSIONS: These results show that HIF-1-active cells constitute a large proportion of invading and metastatic cells and suggest that eradication of these cells may improve the outcome in advanced pancreatic cancer, a condition for which no effective therapy currently exists.
  • [MeSH-major] Hypoxia-Inducible Factor 1 / metabolism. Liver Neoplasms / drug therapy. Pancreatic Neoplasms / drug therapy. Recombinant Fusion Proteins / pharmacology
  • [MeSH-minor] Abdominal Cavity / pathology. Amino Acid Sequence. Animals. Caspase 3 / metabolism. Cell Line, Tumor. Disease Progression. Green Fluorescent Proteins / genetics. Green Fluorescent Proteins / metabolism. Humans. Luciferases / genetics. Luciferases / metabolism. Luminescent Measurements / methods. Male. Mice. Mice, Inbred BALB C. Mice, Nude. Molecular Sequence Data. Neoplasm Invasiveness. Oxygen / metabolism. Peritoneum / drug effects. Peritoneum / metabolism. Peritoneum / pathology. Survival Analysis. Transfection. Xenograft Model Antitumor Assays

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • Genetic Alliance. consumer health - Pancreatic cancer 1.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19417024.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hypoxia-Inducible Factor 1; 0 / Recombinant Fusion Proteins; 0 / TOP3 fusion protein; 147336-22-9 / Green Fluorescent Proteins; EC 1.13.12.- / Luciferases; EC 3.4.22.- / Caspase 3; S88TT14065 / Oxygen
  •  go-up   go-down


3. Choi J, Credit K, Henderson K, Deverkadra R, He Z, Wiig H, Vanpelt H, Flessner MF: Intraperitoneal immunotherapy for metastatic ovarian carcinoma: Resistance of intratumoral collagen to antibody penetration. Clin Cancer Res; 2006 Mar 15;12(6):1906-12
Hazardous Substances Data Bank. Trastuzumab .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraperitoneal immunotherapy for metastatic ovarian carcinoma: Resistance of intratumoral collagen to antibody penetration.
  • PURPOSE: Convective transport of macromolecules from the peritoneal cavity into tumor is determined by its hydraulic permeability and the pressure gradient.
  • Previous studies showed that establishing a pressure gradient into the tumor failed to result in significant penetration.
  • EXPERIMENTAL DESIGN: Human ovarian tumors (SKOV-3 and OVCAR-3) were established in the abdominal wall of athymic rats.
  • After anesthesia, the tumor serosal surface was treated for 2 hours with Krebs solution (control), collagenase (37.5 unit/mL), or hyaluronidase (10 unit/mL) followed by 3 hours of convective delivery of radiolabeled IgG.
  • Transport of antibody into the tumor was measured with quantitative autoradiography along with the tumor interstitial pressure, concentration of collagen and hyaluronic acid, and IgG volume of distribution.
  • RESULTS: Antibody was excluded from 42% to 53% of tumor extracellular volume.
  • Exposure of tumors to hyaluronidase did not enhance IgG transport despite removal of 90% of the hyaluronan from the exposed tumor.
  • In contrast, collagenase reduced collagen content, lowered tumor interstitial pressure, and markedly enhanced antibody penetration.
  • Although high interstitial pressure is a deterrent to convective transport of macromolecules into the tumor parenchyma, the structure of the interstitial matrix provides an inherent resistance, which must be overcome before effective delivery of an antibody.
  • [MeSH-major] Collagen / metabolism. Immunoglobulin G / therapeutic use. Immunotherapy / methods. Ovarian Neoplasms / therapy
  • [MeSH-minor] Animals. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal / pharmacokinetics. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Humanized. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / pharmacokinetics. Antineoplastic Agents / therapeutic use. Biological Transport / drug effects. Cell Line, Tumor. Collagenases / administration & dosage. Extracellular Matrix / metabolism. Female. Humans. Hyaluronoglucosaminidase / administration & dosage. Injections, Intraperitoneal. Neoplasm Metastasis. Rats. Rats, Nude. Trastuzumab. Xenograft Model Antitumor Assays

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16551876.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA085984; United States / NIDDK NIH HHS / DK / DK048479
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Immunoglobulin G; 9007-34-5 / Collagen; EC 3.2.1.35 / Hyaluronoglucosaminidase; EC 3.4.24.- / Collagenases; P188ANX8CK / Trastuzumab
  •  go-up   go-down


Advertisement
4. Bijelic L, Yan TD, Sugarbaker PH: Failure analysis of recurrent disease following complete cytoreduction and perioperative intraperitoneal chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer. Ann Surg Oncol; 2007 Aug;14(8):2281-8
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Failure analysis of recurrent disease following complete cytoreduction and perioperative intraperitoneal chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer.
  • BACKGROUND: The aim of this study was to analyze the anatomic distribution, timing, and outcomes of recurrent disease after complete cytoreduction and perioperative intraperitoneal chemotherapy (PIC) for peritoneal carcinomatosis of colorectal origin.
  • The information regarding recurrent disease found on diagnostic evaluation and/or abdominal exploration was analyzed.
  • RESULTS: Seventy patients underwent complete cytoreduction and perioperative intraperitoneal chemotherapy, and 49 of them had documented recurrent disease.
  • The median time to progression for these 49 patients was 9 months while their median survival was 30 months.
  • Eighteen patients had a localized intra-abdominal recurrence, 10 had diffuse intraperitoneal recurrence, 10 had isolated distant metastases, and 11 had a combination of distant metastases and intra-abdominal recurrence.
  • Four of the 49 patients with recurrences were still alive at the time of last follow-up, and three of them have no evidence of disease 73, 96, and 206 months after the diagnosis of recurrence.
  • Surgical treatment for a selected group of patients with recurrent disease may result in long-term survival.
  • [MeSH-major] Carcinoma / surgery. Colorectal Neoplasms / pathology. Colorectal Neoplasms / surgery. Neoplasm Recurrence, Local. Peritoneal Neoplasms / secondary. Peritoneal Neoplasms / surgery
  • [MeSH-minor] Antibiotics, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / administration & dosage. Biomarkers, Tumor / analysis. Chemotherapy, Adjuvant. Combined Modality Therapy. Drug Administration Schedule. Female. Fluorouracil / administration & dosage. Follow-Up Studies. Humans. Hyperthermia, Induced. Male. Middle Aged. Mitomycin / administration & dosage. Prospective Studies. Radiography, Abdominal. Reoperation / statistics & numerical data. Survival Analysis. Time Factors. Treatment Failure

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg Oncol. 2007 Nov;14(11):3037-9 [17726635.001]
  • (PMID = 17503156.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antimetabolites, Antineoplastic; 0 / Biomarkers, Tumor; 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


5. Han Z, Hong Z, Chen C, Gao Q, Luo D, Fang Y, Cao Y, Zhu T, Jiang X, Ma Q, Li W, Han L, Wang D, Xu G, Wang S, Meng L, Zhou J, Ma D: A novel oncolytic adenovirus selectively silences the expression of tumor-associated STAT3 and exhibits potent antitumoral activity. Carcinogenesis; 2009 Dec;30(12):2014-22
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel oncolytic adenovirus selectively silences the expression of tumor-associated STAT3 and exhibits potent antitumoral activity.
  • Tumor cells acquire the ability to proliferate uncontrollably, resist apoptosis, sustain angiogenesis and evade immune surveillance.
  • Consequently, the STAT3 protein is emerging as an ideal target for cancer therapy.
  • This paper reports the generation of an oncolytic adenovirus (M4), which selectively blocks STAT3 signaling in tumor cells as a novel therapeutic strategy.
  • M4 selectively replicated in tumor cells and expressed high levels of antisense STAT3 complementary DNA during the late phase of the viral infection in a replication-dependent manner.
  • The viral progeny yield of M4 in tumor cells was much higher than that of the parent adenoviral mutants, Ad5/dE1A.
  • M4 effectively silenced STAT3 and its target genes in tumor cells while sparing normal cells and exhibited potent antitumoral efficacy in vitro and in vivo.
  • Systemic administration of M4 significantly inhibited tumor growth in an orthotopic gastric carcinoma mouse model, eliminated abdominal cavity metastases and prolonged survival time.
  • In summary, M4 has low toxicity and great potential as a therapeutic agent for different types of cancers.
  • [MeSH-minor] Animals. Apoptosis. Cell Line, Tumor. Collagen / chemistry. Drug Combinations. Humans. Laminin / chemistry. Male. Mice. Mice, Inbred BALB C. Models, Genetic. Mutation. Neoplasm Metastasis. Neovascularization, Pathologic. Oligonucleotides, Antisense / genetics. Proteoglycans / chemistry. Signal Transduction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19843641.001).
  • [ISSN] 1460-2180
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Drug Combinations; 0 / Laminin; 0 / Oligonucleotides, Antisense; 0 / Proteoglycans; 0 / STAT3 Transcription Factor; 0 / STAT3 protein, human; 119978-18-6 / matrigel; 9007-34-5 / Collagen
  •  go-up   go-down


6. Shimakawa T, Naritaka Y, Asaka S, Isohata N, Yamaguchi K, Murayama M, Konno S, Katsube T, Ogawa K, Ide H: A case of esophageal cancer with multiple lymph node metastases which responded to neoadjuvant chemotherapy (DCF therapy). Anticancer Res; 2010 Jan;30(1):221-6
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of esophageal cancer with multiple lymph node metastases which responded to neoadjuvant chemotherapy (DCF therapy).
  • It is difficult to perform radical surgery for esophageal cancer with multiple lymph node metastases.
  • Therefore, effective neoadjuvant adjuvant treatment is necessary to achieve successful radical resection.
  • The use of neoadjuvant chemotherapy of docetaxel, cisplatin (CDOP) and 5-fluorouracil (5-FU) (DCF) in an advanced case is reported.
  • The patient (a 67-year-old female) was diagnosed with esophageal cancer, T3, N4, M0, stage IVa with a large number of lymph node metastases in the mediastinum and in the abdominal cavity.
  • Neoadjuvant DCF chemotherapy was initiated in August 2006.
  • A complete response of the lymph node metastases in the abdominal cavity and a partial response of the esophageal lesion were achieved.
  • The surgical procedure included a right thoracolaparotomy followed by a subtotal excision of the esophagus and two-field lymph node dissection.
  • The histological efficacy of the chemotherapy was determined to be grade 1a.
  • Two additional courses of DCF therapy were administered followed by postoperative adjuvant chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Esophageal Neoplasms / drug therapy
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Lymphatic Metastasis. Neoadjuvant Therapy. Neoplasm Staging. Taxoids / administration & dosage

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20150639.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


7. Nakajima Y, Gotanda T, Uchimiya H, Furukawa T, Haraguchi M, Ikeda R, Sumizawa T, Yoshida H, Akiyama S: Inhibition of metastasis of tumor cells overexpressing thymidine phosphorylase by 2-deoxy-L-ribose. Cancer Res; 2004 Mar 1;64(5):1794-801
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of metastasis of tumor cells overexpressing thymidine phosphorylase by 2-deoxy-L-ribose.
  • In this study, we examined the ability of L-dRib to suppress metastasis of KB/TP cells using two different models of metastasis.
  • The antimetastatic effect of L-dRib was first investigated in a liver-metastasis model in nude mice inoculated with KB/TP cells.
  • Oral administration of L-dRib for 28 days at a dose of 20 mg/kg/day significantly reduced the number of metastatic nodules in the liver and suppressed angiogenesis and enhanced apoptosis in KB/TP metastatic nodules.
  • Next, we compared the ability of L-dRib and tegafur alone or in combination to decrease the number of metastatic nodules in organs in the abdominal cavity in nude mice receiving s.c. of KB/TP cells into their backs.
  • L-dRib (20 mg/kg/day) was significantly (P < 0.05) more efficient than tegafur (100 mg/kg/day) in decreasing the number of metastatic nodules in organs in the abdominal cavity.
  • These findings suggest that L-dRib may be useful in a clinical setting for the suppression of metastasis of tumor cells expressing TP.
  • [MeSH-major] Deoxyribose / therapeutic use. Neoplasm Metastasis / prevention & control. Thymidine Phosphorylase / physiology
  • [MeSH-minor] Animals. Apoptosis / drug effects. Drug Therapy, Combination. Interleukin-8 / genetics. Liver Neoplasms / prevention & control. Liver Neoplasms / secondary. Male. Mice. Neoplasm Invasiveness. Neoplasms, Experimental / drug therapy. Neovascularization, Pathologic / prevention & control. Tegafur / therapeutic use. Vascular Endothelial Growth Factor A / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14996742.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-8; 0 / Vascular Endothelial Growth Factor A; 1548R74NSZ / Tegafur; 533-67-5 / Deoxyribose; EC 2.4.2.4 / Thymidine Phosphorylase
  •  go-up   go-down


8. Hohenberger P, Ronellenfitsch U, Oladeji O, Pink D, Ströbel P, Wardelmann E, Reichardt P: Pattern of recurrence in patients with ruptured primary gastrointestinal stromal tumour. Br J Surg; 2010 Dec;97(12):1854-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: The records of 23 patients (8 women, 15 men; median age 54 years) with ruptured primary non-metastatic GIST were retrieved from a database of 554 patients.
  • RESULTS: Tumour rupture was spontaneous in 16 patients, following abdominal trauma in two and occurred during resection in five.
  • Fifteen of 16 patients who did not receive adjuvant therapy developed tumour recurrence after a median of 19 months.
  • CONCLUSION: Patients with a rupture of GIST into the abdominal cavity have a risk of recurrence of nearly 100 per cent.
  • All patient groups are clear candidates for adjuvant drug therapy.
  • [MeSH-major] Gastrectomy. Gastrointestinal Stromal Tumors / pathology. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Female. Humans. Male. Middle Aged. Mutation. Neoplasm Metastasis. Platelet-Derived Growth Factor / genetics. Prognosis. Risk Factors. Rupture, Spontaneous. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.
  • (PMID = 20730857.001).
  • [ISSN] 1365-2168
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Platelet-Derived Growth Factor; 0 / platelet-derived growth factor A
  •  go-up   go-down


9. Stanclift RM, Gilson SD: Use of cisplatin, 5-fluorouracil, and second-look laparotomy for the management of gastrointestinal adenocarcinoma in three dogs. J Am Vet Med Assoc; 2004 Nov 1;225(9):1412-7, 1393
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Three dogs with advanced-stage adenocarcinoma of the gastrointestinal tract were treated by use of resection, adjuvant chemotherapy with cisplatin and 5-fluorouracil, and second-look laparotomy (SLL).
  • In combination with histologic examination of biopsy specimens obtained during the procedure, SLL is the most accurate diagnostic procedure for identification of residual or recurrent microscopic or macroscopic abdominal neoplasia; however, to the authors' knowledge, there are no reports of its clinical use in the field of veterinary oncology.
  • This lack of clinical use in animals is likely because of factors such as cost, procedure-associated risks perceived by the owners and veterinarians, lack of data to define proper clinical application, and, perhaps to some degree, an entrenched belief that treatment of advanced stage cancer in animals is inappropriate.
  • Nevertheless, the use of SLL should be considered for evaluation of abdominal tumors or intra-abdominal metastases in dogs that appear to be in complete clinical remission near or at the anticipated completion of chemotherapy (especially if effective second-line chemotherapy protocols are available) or when secondary cytoreduction might be beneficial.
  • [MeSH-major] Adenocarcinoma / veterinary. Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Fluorouracil / therapeutic use. Gastrointestinal Neoplasms / veterinary. Neoplasm Recurrence, Local / veterinary
  • [MeSH-minor] Animals. Dogs. Female. Laparotomy / veterinary. Male. Reoperation / veterinary. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15552318.001).
  • [ISSN] 0003-1488
  • [Journal-full-title] Journal of the American Veterinary Medical Association
  • [ISO-abbreviation] J. Am. Vet. Med. Assoc.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


10. Sandruck J, Escobar P, Lurain J, Fishman D: Uterine leiomyosarcoma metastatic to the sphenoid sinus: a case report and review of the literature. Gynecol Oncol; 2004 Feb;92(2):701-4
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Uterine leiomyosarcoma metastatic to the sphenoid sinus: a case report and review of the literature.
  • BACKGROUND: Leiomyosarcoma (LMS) of the uterus is a rare neoplasm with an aggressive growth pattern.
  • The most common sites of recurrent disease are lung, liver, and peritoneal cavity.
  • Metastases to brain and skull are rare.
  • CASE: A 39-year-old woman underwent a total abdominal hysterectomy, bilateral salpingo-oophorectomy, pelvic and paraaortic lymph node biopsies, omentectomy, and appendectomy for Grade 2 FIGO Stage 1 uterine leiomyosarcoma.
  • She remained disease-free for 2 years until she presented with metastases to the sphenoid sinus.
  • She underwent incomplete resection of the recurrence and was treated postoperatively with adjuvant MAID chemotherapy with poor response.
  • Five months later, she was treated with radiation therapy to the base of the skull with no response.
  • The treatment options are limited.
  • Surgical management should be considered as uterine LMS has a low response to chemotherapy and surgical resection of LMS to sites such as lung and abdomen has been suggested to offer a benefit.
  • Radiation therapy may provide palliative benefit in the setting of metastatic disease.

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14766270.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 31
  •  go-up   go-down


11. Lehnert T, Rudek B, Kienle P, Buhl K, Herfarth C: Impact of diagnostic laparoscopy on the management of gastric cancer: prospective study of 120 consecutive patients with primary gastric adenocarcinoma. Br J Surg; 2002 Apr;89(4):471-5
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Peritoneal seeding or liver metastases found at laparotomy usually preclude curative treatment in patients with gastric adenocarcinoma.
  • Diagnostic laparoscopy was performed in patients with clinical T4 tumours or suspected metastases, unless laparotomy was required for symptomatic disease.
  • Fifteen patients underwent diagnostic laparoscopy, which identified intra-abdominal metastases in six; the other nine patients proceeded to laparotomy, which revealed peritoneal metastases not detected at laparoscopy in four patients.
  • The remaining nine patients had overt metastases and were referred for systemic chemotherapy without abdominal exploration.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Algorithms. Female. Humans. Liver Neoplasms / secondary. Male. Middle Aged. Prospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Br J Surg. 2002 Oct;89(10):1326; author reply 1326 [12296911.001]
  • [CommentIn] Br J Surg. 2002 Oct;89(10):1325-6; author reply 1326 [12296914.001]
  • (PMID = 11952590.001).
  • [ISSN] 0007-1323
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


12. Dauplat J: [Management of ovarian cancer]. Cancer Radiother; 2001 Nov;5 Suppl 1:149s-161s
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Prise en charge du cancer de l'ovaire.
  • Advanced stages are usually characterized by a large tumor burden on the ovaries as well as metastatic disease in the peritoneal cavity.
  • Early stages are more common in young women and the surgical treatment should comprise the tumor excision and a comprehensive abdominal staging to be sure that there is no extension beyond the ovaries--unilateral oophorectomy can preserve the fertility before childbearing.
  • No treatment is needed after surgery in stage I without poor prognostic factors.
  • Adjuvant chemotherapy should be applied postoperatively in the other cases.
  • The best likelihood of prolonged survival is observed after optimal debulking surgery and chemotherapy in advanced stages.
  • If possible surgery should be performed at first but in most advanced stage with large tumor volume in the upper abdomen according to clinical and CT-scan examination, the concept of chemosurgical debulking should be considered.
  • Interval surgery underwent after three or four courses of front line chemotherapy but this strategy should be further evaluated by clinical trials.
  • Thank to aggressive surgery and chemotherapy many patients should be able to reach a complete remission of their disease but most of them will still die of recurrent disease.
  • 1) how to manage the residual abdominal disease in order to prevent the recurrence.
  • No consolidation treatment demonstrated any superiority but the French experience and trial with high dose chemotherapy supported by autologous stem cells transplantation showed recently positive results?
  • 2) How to manage the recurrent disease with sometime indication for secondary surgical debulking and always chemotherapy?
  • This is the field for testing new drugs or new strategies.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasm Recurrence, Local / prevention & control. Neoplasm Staging. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / surgery
  • [MeSH-minor] Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Hematopoietic Stem Cell Transplantation. Humans. Patient Care Planning. Prognosis. Randomized Controlled Trials as Topic. Survival Analysis. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Ovarian cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11797275.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


13. Kodama M, Kawaguchi H, Komoto Y, Takemura M: Coexistent intramedullary spinal cord and choroidal metastases in ovarian cancer. J Obstet Gynaecol Res; 2010 Feb;36(1):199-203
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Coexistent intramedullary spinal cord and choroidal metastases in ovarian cancer.
  • Involvement of intramedullary spinal cord and the choroid by ovarian cancer is rare, and coexistence of metastases at these sites is extremely rare and has never been reported.
  • This condition rapidly progresses to a neurological emergency; however, an efficient standard treatment method is not available for this rare condition.
  • She presented with blindness and other neurologic complaints during the course of treatment for a recurrence at 50 months after the primary surgical treatment for the tumor.
  • Magnetic resonance imaging (MRI) revealed intramedullary spinal cord metastasis and choroidal metastasis, coexisting with multiple brain metastases and intra-abdominal lesions.
  • Neurological emergency was prevented by administering whole-brain irradiation therapy followed by systemic chemotherapy.
  • Early diagnosis and multidisciplinary treatment, including radiotherapy and chemotherapy, may offer good palliation for such unusual metastases of ovarian cancer.
  • [MeSH-major] Brain Neoplasms / secondary. Choroid Neoplasms / secondary. Cystadenocarcinoma, Serous / secondary. Neoplasm Recurrence, Local. Ovarian Neoplasms / pathology. Spinal Cord Neoplasms / secondary
  • [MeSH-minor] Abdominal Neoplasms / secondary. Abdominal Neoplasms / therapy. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Hysterectomy. Ovariectomy

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20178552.001).
  • [ISSN] 1447-0756
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


14. Perilongo G, Shafford E, Maibach R, Aronson D, Brugières L, Brock P, Childs M, Czauderna P, MacKinlay G, Otte JB, Pritchard J, Rondelli R, Scopinaro M, Staalman C, Plaschkes J, International Society of Paediatric Oncology-SIOPEL 2: Risk-adapted treatment for childhood hepatoblastoma. final report of the second study of the International Society of Paediatric Oncology--SIOPEL 2. Eur J Cancer; 2004 Feb;40(3):411-21
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk-adapted treatment for childhood hepatoblastoma. final report of the second study of the International Society of Paediatric Oncology--SIOPEL 2.
  • SIOPEL 2 was a pilot study designed to test the efficacy and toxicity of two chemotherapy (CT) regimens, one for patients with hepatoblastoma (HB) confined to the liver and involving no more than three hepatic sectors ('standard-risk (SR) HB'), and one for those with HB extending into all four sectors and/or with lung metastases or intra-abdominal extra hepatic spread 'high-risk (HR) HB'.
  • A treatment strategy based on CDDP monotherapy and surgery thus appears effective in SR-HB but, despite CT intensification, only half of the HR-HB patients are long-term survivors.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hepatoblastoma / drug therapy. Liver Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Carboplatin / administration & dosage. Carboplatin / adverse effects. Child. Child, Preschool. Cisplatin / administration & dosage. Cisplatin / adverse effects. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Female. Humans. Infant. Male. Pilot Projects. Risk Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Hepatoblastoma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14746860.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 80168379AG / Doxorubicin; BG3F62OND5 / Carboplatin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


15. Catani M, De Milito R, Simi M: [New orientations in the management of advanced, metastatic gastrointestinal stromal tumors (GIST): combination of surgery and systemic therapy with imatinib in a case of primary gastric location]. Chir Ital; 2005 Jan-Feb;57(1):127-33
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [New orientations in the management of advanced, metastatic gastrointestinal stromal tumors (GIST): combination of surgery and systemic therapy with imatinib in a case of primary gastric location].
  • [Transliterated title] Nuovi orientamenti nella cura dei tumori stromali gastroenterici (GIST) avanzati e metastatici: trattamento combinato intervento chirurgico-terapia sistemica con imatinib in un caso a localizzazione primitiva gastrica.
  • Gastrointestinal stromal tumours (GIST) are rare neoplasms originating from connective tissue in the digestive tract with an incidence of less than 1% and account for most non-epithelial primitive digestive tumours.
  • Metastasis diagnosed at the time of disease discovery confirms GIST malignancy.
  • Resistance to conventional chemotherapy is commonly shown by malignant GIST.
  • Most patients with advanced malignant GIST achieve clinical benefit with imatinib mesilate, an orally administered selective inhibitor of the tyrosine kinase receptor.
  • At the time of the first operation the patient had lost 10 kg body weight over the previous months and was seriously cachectic.
  • A total body CT scan documented the substantial size of the gastric wall lesion, an increased volume of abdominal lymph nodes and compression of the splenic vein with alternative collateral circulation.
  • The liver presented no less than 5 large metastases distributed in both the left and right lobes.
  • There was also a pulmonary metastasis.
  • Considering the action mechanism of imatinib and the extent of the lesion we decided to perform a total gastrectomy procedure.
  • At the time of the operation the stomach seemed to have a modified volume and shape: it appeared to be divided into two sacs, the larger and deeper of which was the original gastric cavity, while the superficial, smaller one seemed to be a protrusion of the organ.
  • The stomach was indistinguishable from the spleen, the transverse colon and the distal pancreatic tract.
  • The neoplasm was directly linked to the left liver and to the inferior diaphragmatic surface.
  • The patient was discharged on postoperative day 8 and commenced imatinib therapy 30 days after the operation with 4 tablets per day.
  • One year after the operation the outcome appears to be lasting and the patient has tolerated the drug treatment well.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Gastrectomy. Gastrointestinal Stromal Tumors / therapy. Piperazines / therapeutic use. Pyrimidines / therapeutic use. Stomach Neoplasms / therapy
  • [MeSH-minor] Adult. Benzamides. Humans. Imatinib Mesylate. Male. Treatment Outcome

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15832750.001).
  • [ISSN] 0009-4773
  • [Journal-full-title] Chirurgia italiana
  • [ISO-abbreviation] Chir Ital
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


16. Nevelsteen I, De Wever I, Stas M, Devroe H, Dumez H, Van Oosterom A: Surgical interventions during STI 571 treatment of metastatic GIST: experience in six patients. Acta Chir Belg; 2004 Nov-Dec;104(6):683-9
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical interventions during STI 571 treatment of metastatic GIST: experience in six patients.
  • Until recently, surgery was the only treatment available because these tumours were not sensitive to chemotherapy nor radiation therapy.
  • In the long run most of these tumours recurred in the abdominal cavity or in the liver.
  • Recently a new drug STI 573 (Glivec) showed very promising results in metastatic disease with response rates of about 65%.
  • In six patients treated at our center, surgery was indicated during STI therapy because of subobstruction, skin necrosis, abdominal distention, bleeding.
  • Surgery proved to be safe and efficient, allowing continuation of STI therapy in much better circumstances.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Gastrointestinal Neoplasms / drug therapy. Gastrointestinal Neoplasms / surgery. Gastrointestinal Stromal Tumors / drug therapy. Gastrointestinal Stromal Tumors / surgery. Piperazines / therapeutic use. Pyrimidines / therapeutic use
  • [MeSH-minor] Adult. Aged. Benzamides. Combined Modality Therapy. Female. Humans. Imatinib Mesylate. Male. Middle Aged. Neoplasm Metastasis. Surgical Procedures, Operative / methods. Treatment Outcome

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15663275.001).
  • [ISSN] 0001-5458
  • [Journal-full-title] Acta chirurgica Belgica
  • [ISO-abbreviation] Acta Chir. Belg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Belgium
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


17. Bai FH, Yang L, Ji Q, Zhang YQ, Liu ZX, Wang ZZ, Yan L, Wang JB, Jin HF, Li TT: [Intraoperative and postoperative intra-peritoneal administration of peptide PIII inhibits peritoneal metastasis of gastric cancer]. Zhonghua Yi Xue Za Zhi; 2006 Dec 12;86(46):3260-3
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Intraoperative and postoperative intra-peritoneal administration of peptide PIII inhibits peritoneal metastasis of gastric cancer].
  • OBJECTIVE: To evaluate the preventive potential of intraoperative or early postoperative local administration of peptide PIII into the abdominal cavity against peritoneal carcinomatosis.
  • The tumor-bearing mice showing manifestations of failure were killed to undergo pathology.
  • RESULTS: The weight of individual tumor was not significantly different among the 3 groups.
  • The number of peritoneal metastatic nodules of Group 2 was (9.2 +/- 1.3), significantly less than those of Group 1 and 3 [(126.3 +/- 9.6) and (64.2 +/- 8.3) respectively, both P < 0.01].
  • The number of metastatic nodules > 2 mm of Group 2 was 1.6 +/- 0.2, significantly less then those of Groups 1 and 3 [(51.2 +/- 3.6) and (21.7 +/- 4.9) respectively, both P < 0.01].
  • CONCLUSION: Peptide PIII does not significantly inhibit the growth of GC, but significantly reduce the peritoneal metastasis of GC.
  • An ideal targeting chemotherapy, intra-operative application of peptide PIII into the abdominal cavity plus intraperitoneal perfusion is an attractive and promising strategy to prevent peritoneal metastasis of GC.
  • [MeSH-major] Peptides / therapeutic use. Peritoneal Neoplasms / prevention & control. Stomach Neoplasms / drug therapy. Xenograft Model Antitumor Assays
  • [MeSH-minor] Animals. Cell Line, Tumor. Female. Humans. Injections, Intraperitoneal. Intraoperative Care. Male. Mice. Mice, Inbred BALB C. Mice, Nude. Neoplasm Seeding. Postoperative Care

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17313805.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Peptides
  •  go-up   go-down


18. Hohenberger P: [Gastrointestinal stromal tumors]. Praxis (Bern 1994); 2007 Jan 10;96(1-2):29-33
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gastro-intestinal stromal tumors (GIST), an abdominal sarcoma entity are characterized by a gain-of-function mutation in c-kit proto-oncogen (CD117).
  • Initial treatment should aim at complete removal of the primary tumor (R0 resection) which almost never develops lymphatic metastases.
  • Distant metastatic spread involves mainly the peritoneal cavity and the liver.
  • In patients with metastatic disease, treatment with tyrosinkinase inhibitor imatinib mesylate (Glivec) is indicated and very effective.
  • Systemic chemotherapy and external beam radiation must be considered ineffective.
  • Patients requiring multivisceral resection to remove their primary tumor rapidly develop tumor recurrence and could potentially benefit from preoperative treatment with imatinib.
  • Whether there is an advantage of adjuvant treatment is currently under investigation within international randomized trials.
  • Patients who develop an extensive remission of metastatic disease should be evaluated individually for resection of the tumor remnants.
  • Even resection of single progressive lesions (with newly developed mutations) should be considered in carefully selected patients, if the remaining tumor can be controlled by continued imatinib treatment.
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Benzamides. Chemotherapy, Adjuvant. Disease Progression. Female. Humans. Imatinib Mesylate. Male. Middle Aged. Mutation. Neoplasm Metastasis. Piperazines / therapeutic use. Prognosis. Protein Kinase Inhibitors / therapeutic use. Proto-Oncogene Proteins c-kit / genetics. Pyrimidines / therapeutic use. Randomized Controlled Trials as Topic. Risk Factors

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17256558.001).
  • [ISSN] 1661-8157
  • [Journal-full-title] Praxis
  • [ISO-abbreviation] Praxis (Bern 1994)
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  • [Number-of-references] 28
  •  go-up   go-down


19. Isaacs H Jr: Fetal and neonatal hepatic tumors. J Pediatr Surg; 2007 Nov;42(11):1797-803
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The purpose of this review is to focus on the fetus and neonate in an attempt to determine the various ways liver tumors differ clinically and pathologically from those found in the older child and adult and to show that certain types of tumors have a better prognosis than others.
  • There was some relationship between histologic type and prognosis.
  • Fifteen of 32 hepatoblastoma patients received surgical resection with or without chemotherapy, resulting in 7 (47%) of 15 cures.
  • However, there are fatal complications associated with this tumor, ie, fetal hydrops, respiratory distress, and circulatory problems owing to a large space occupying abdominal lesion and sometimes stillbirth, all contributing to the death rate.
  • Pre- or postoperative chemotherapy is reserved for those patients with unresectable tumors or metastatic disease.
  • Patients die from the mass effect caused by the tumor, which lead to abdominal distension, vascular compromise, anemia, hydrops, respiratory distress, and stillbirth.
  • Metastases to the abdominal cavity, lungs, and placenta are other causes of death.
  • Because of the danger of labor-induced rupture of the tumor and potentially fatal intraabdominal hemorrhage, cesarean delivery is recommended when a hepatic tumor is found on prenatal ultrasound.

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18022426.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 24
  •  go-up   go-down


20. Huang SG, Kong BH, Yang RF, Jiang S: [Primary study of arsenic trioxide inhibits abdomino-metastatic tumor formation of human ovarian carcinoma in nude mice and its mechanisms]. Ai Zheng; 2002 Apr;21(4):401-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary study of arsenic trioxide inhibits abdomino-metastatic tumor formation of human ovarian carcinoma in nude mice and its mechanisms].
  • The objective of this study was to explore the inhibitory effect of As2O3 on the abdomino-metastasis of human ovarian carcinoma in nude mice and its mechanisms.
  • METHODS: Compared with cisplatin(cDDP), the growth inhibiting rates to human ovarian cancer cell line 3AO by treatment with various concentrations of As2O3 for 48 h were determined by methyl thiazolyl tetrazolium(MTT) method.
  • After implanted with 3AO cells 4 x 10(6) into abdominal cavity for 96 h, the nude mice were randomly divided into 5 groups and treated by intraperitoneal injection of normal saline, cisplatin, or different concentrations of As2O3.
  • The rate of tumor formation, death rate, and survival period of tumor-bearing nude mice were evaluated.
  • After treatment with As2O3, the changes of Fas, FasL, and nm23 gene expressions were estimated by flow cytometry (FCM).
  • RESULTS: Compared with cisplatin, 3AO cell growth inhibiting rates by As2O3 were different significantly in concentration-dependent manner (P < 0.05); Compared with cisplatin, As2O3 could reduce the 3AO cell tumor formation rate in nude mice and the death rate of tumor-bearing nude mice, and prolong the survival period of tumor-bearing nude mice significantly (P < 0.05).
  • As2O3 up-regulated Fas and nm23 gene expressions of abdominal cavity implanted tumors (P < 0.05), but did not affect FasL gene expression (P > 0.05).
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Arsenicals / therapeutic use. Neoplasms, Experimental / drug therapy. Nucleoside-Diphosphate Kinase. Ovarian Neoplasms / pathology. Oxides / therapeutic use
  • [MeSH-minor] Animals. Antigens, CD95 / biosynthesis. Disease Models, Animal. Fas Ligand Protein. Female. Humans. Membrane Glycoproteins / biosynthesis. Mice. Mice, Nude. Monomeric GTP-Binding Proteins / biosynthesis. NM23 Nucleoside Diphosphate Kinases. Neoplasm Metastasis. Neoplasm Transplantation. Transcription Factors / biosynthesis. Treatment Outcome. Tumor Cells, Cultured. Xenograft Model Antitumor Assays

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12452020.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD95; 0 / Antineoplastic Agents; 0 / Arsenicals; 0 / FASLG protein, human; 0 / Fas Ligand Protein; 0 / Fasl protein, mouse; 0 / Membrane Glycoproteins; 0 / NM23 Nucleoside Diphosphate Kinases; 0 / Oxides; 0 / Transcription Factors; EC 2.7.4.6 / NME1 protein, human; EC 2.7.4.6 / Nme1 protein, mouse; EC 2.7.4.6 / Nucleoside-Diphosphate Kinase; EC 3.6.5.2 / Monomeric GTP-Binding Proteins; S7V92P67HO / arsenic trioxide
  •  go-up   go-down


21. Kratz KG, Santillan A, Gu M, Bristow RE: Radical surgical cytoreduction of progressive leiomyomatosis peritonealis disseminata: a case report. J Reprod Med; 2009 Jul;54(7):447-50

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Leiomyomatosis peritonealis disseminata (LPD) is an uncommon, benign smooth muscle condition of the peritoneal cavity that appears clinically as a metastatic malignant neoplasm.
  • This unique case involves curative radical surgery after disease progression during depo-medroxyprogesterone acetate therapy.
  • CASE: A 31-year-old woman presented with abdominal pain and uterine leiomyomas.
  • Despite initial surgery and hormonal therapy, she had progression of disease.
  • Tumor response to megestrol acetate in vitro was evaluated and noted to be heterogeneous; therefore it was not given as adjuvant therapy.
  • Five years after radical surgery, she was without evidence of disease, CONCLUSION: Radical secondary cytoreductive surgery can achieve a durable remission for LPD refractory to primary surgical castration and depomedroxyprogesterone acetate therapy.
  • [MeSH-minor] Adult. Disease Progression. Dose-Response Relationship, Drug. Female. Humans. Medroxyprogesterone Acetate / administration & dosage. Peritoneal Cavity / cytology. Peritoneal Cavity / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19691262.001).
  • [ISSN] 0024-7758
  • [Journal-full-title] The Journal of reproductive medicine
  • [ISO-abbreviation] J Reprod Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] C2QI4IOI2G / Medroxyprogesterone Acetate
  •  go-up   go-down


22. Hohenberger P, Wardelmann E: [Surgical considerations for gastrointestinal stroma tumor]. Chirurg; 2006 Jan;77(1):33-40
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical considerations for gastrointestinal stroma tumor].
  • [Transliterated title] Gastrointestinale Stromatumoren. Was der Chirurg wissen muss.
  • Gastrointestinal stroma tumors (GIST), an abdominal stroma entity, are characterized by a gain-in-function mutation in the c-kit proto-oncogen (CD117).
  • Initial treatment should aim at complete removal of the primary tumor (R0 resection), which almost never develops lymphatic metastases.
  • Distant metastatic spread mainly involves the peritoneal cavity and the liver.
  • In patients with metastatic disease, treatment with the tyrosine kinase inhibitor imatinib mesylate is indicated and very effective.
  • Systemic chemotherapy and external beam radiation must be considered ineffective.
  • Patients requiring multivisceral resection for primary tumor removal quickly develop tumor recurrence and could benefit from preoperative treatment with imatinib.
  • To assess the response to treatment, 18F-FDG positron emission tomography or gadolinium-enhanced magnetic resonance imaging have proven helpful, as the conventional criteria of tumor shrinkage according to WHO standards are rarely met.
  • The possible advantages of adjuvant treatment are currently under investigation through international randomized trials.
  • Patients who develop extensive remission of metastatic disease should be evaluated individually for resection of the tumor remnants.
  • Even the resection of single progressive lesions (newly developed mutations) should be considered in carefully selected patients if the remaining tumor can be controlled by continued imatinib treatment.
  • [MeSH-minor] Antigens, CD34 / genetics. Apoptosis / physiology. Biomarkers, Tumor / genetics. DNA Mutational Analysis. Gastrointestinal Tract / pathology. Gene Expression Regulation, Neoplastic / physiology. Genes, ras / genetics. Humans. Lymphatic Metastasis / pathology. Neoplasm Staging. Prognosis. Proto-Oncogene Proteins c-kit / genetics

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 2000 Jan;231(1):51-8 [10636102.001]
  • [Cites] Cancer Genet Cytogenet. 2000 Jul 15;120(2):111-6 [10942800.001]
  • [Cites] Eur Radiol. 2005 Dec;15(12):2448-56 [16132930.001]
  • [Cites] Arch Surg. 2001 Apr;136(4):383-9 [11296107.001]
  • [Cites] Am J Surg Pathol. 2005 Sep;29(9):1170-6 [16096406.001]
  • [Cites] N Engl J Med. 2001 Apr 5;344(14):1052-6 [11287975.001]
  • [Cites] Z Gastroenterol. 2005 Sep;43(9):1025-30 [16142610.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23(24):5795-804 [16110036.001]
  • [Cites] N Engl J Med. 2002 Aug 15;347(7):472-80 [12181401.001]
  • [Cites] Rofo. 2003 Jun;175(6):791-8 [12811692.001]
  • [Cites] Lancet. 2004 Sep 25-Oct 1;364(9440):1127-34 [15451219.001]
  • [Cites] Gastroenterology. 2005 Sep;129(3):1042-6 [16143141.001]
  • [Cites] Histopathology. 2003 Aug;43(2):118-26 [12877726.001]
  • [Cites] J Clin Oncol. 2002 Sep 15;20(18):3898-905 [12228211.001]
  • [Cites] Mod Pathol. 2002 Feb;15(2):125-36 [11850541.001]
  • [Cites] Am J Pathol. 1998 May;152(5):1259-69 [9588894.001]
  • [Cites] Science. 1998 Jan 23;279(5350):577-80 [9438854.001]
  • [Cites] Gastroenterology. 2002 May;122(5):1493-9 [11984533.001]
  • [Cites] Am J Gastroenterol. 2005 Jan;100(1):162-8 [15654796.001]
  • [Cites] Lancet Oncol. 2005 Apr;6(4):249-51 [15811621.001]
  • [Cites] J Clin Oncol. 2000 Sep 15;18(18):3211-20 [10986053.001]
  • [Cites] Med Sci Monit. 2004 Aug;10(8):LE13-4 [15278004.001]
  • [Cites] J Clin Pathol. 2004 Feb;57(2):215-7 [14747457.001]
  • [Cites] Pathologe. 2003 May;24(3):182-91 [12739051.001]
  • [Cites] Br J Cancer. 2003 Aug 4;89(3):460-4 [12888812.001]
  • [Cites] Ann Oncol. 2005 Apr;16(4):566-78 [15781488.001]
  • [Cites] Cancer. 2005 Feb 15;103(4):821-9 [15648083.001]
  • [Cites] Eur J Cancer. 2003 Sep;39(14 ):2012-20 [12957455.001]
  • [Cites] Hum Pathol. 2002 Mar;33(3):316-21 [11979372.001]
  • [Cites] Mayo Clin Proc. 1999 Jun;74(6):543-52 [10377927.001]
  • [Cites] Lancet. 2001 Oct 27;358(9291):1421-3 [11705489.001]
  • (PMID = 16372188.001).
  • [ISSN] 0009-4722
  • [Journal-full-title] Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Biomarkers, Tumor; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


23. Wolf JK, Bodurka DC, Gano JB, Deavers M, Ramondetta L, Ramirez PT, Levenback C, Gershenson DM: A phase I study of Adp53 (INGN 201; ADVEXIN) for patients with platinum- and paclitaxel-resistant epithelial ovarian cancer. Gynecol Oncol; 2004 Aug;94(2):442-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • EXPERIMENTAL DESIGN: Eligibility criteria included patients with platinum- and paclitaxel-resistant metastatic epithelial ovarian cancer; a Zubrod performance status of 0, 1, or 2; and adequate bone marrow, liver, and renal function.
  • All but one patient received two or more chemotherapy regimens before study entry.
  • Grade 3 toxicities included fatigue (six patients), fever (two patients), chills (one patient), abdominal pain (three patients), nausea (two patients), and sinus congestion (one patient).
  • With a negative randomized trial of ovarian cancer in front-line treatment that included an adenovirus p53 plus chemotherapy, we feel that further refinement of gene therapy is required before additional trials are undertaken.
  • It also tends to recur and progress within the abdominal cavity.
  • Because of this, regional intraperitoneal therapy for ovarian cancer is attractive.
  • Common toxicities were abdominal pain, fever, and chills.
  • The best mechanism of delivery of gene therapy for patients is unclear, however, no severe toxicities were found using an adenovirus-mediated p53 gene in this group heavily pretreated patients with recurrent ovarian cancer.
  • [MeSH-major] Genes, p53 / genetics. Genetic Therapy / methods. Ovarian Neoplasms / therapy
  • [MeSH-minor] Adenoviruses, Human / genetics. Adult. Aged. Drug Resistance, Neoplasm. Feasibility Studies. Female. Humans. Injections, Intraperitoneal. Middle Aged. Organoplatinum Compounds / pharmacology. Paclitaxel / pharmacology


24. Angioli R, Palaia I, Damiani P, Montera R, Benedetti Panici P: [Up-date on cytoreductive surgery in the management of advanced ovarian cancer]. Minerva Ginecol; 2006 Dec;58(6):459-70
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Epithelial ovarian cancer represents the most aggressive neoplasm of women genital apparatus with a total 5-year survival rate ranging from 17% to 35% if the disease is in the metastatic phase.
  • Its aggressiveness derives from the fact that it is an asymptomatic disease until it spreads in abdominal cavity.
  • Therefore, in 70% of the cases, the diagnosis is done when tumor is already in advanced phase (Stage FIGO IIB-IV).
  • Data from international literature suggest that standard treatment for advanced ovarian cancer is optimal cytoreductive surgery with adjuvant chemotherapy platinum-based.
  • However, in the last decades, many authors have described the enthusiastic results of neoadjuvant chemotherapy and interval debulking surgery.
  • Ovarian cancer turns out to be a particularly chemosensitive tumor.
  • Its responsiveness has been the object of numerous studies and protocols in literature, such as European Organisation of Research and Treatment of Cancer (EORTC) and Gynecologic Oncology Group (GOG) trials.
  • [MeSH-minor] Chemotherapy, Adjuvant. Disease Progression. Female. Gynecologic Surgical Procedures / methods. Humans. Neoadjuvant Therapy. Prognosis

  • Genetic Alliance. consumer health - Ovarian cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17108876.001).
  • [ISSN] 0026-4784
  • [Journal-full-title] Minerva ginecologica
  • [ISO-abbreviation] Minerva Ginecol
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 43
  •  go-up   go-down


25. Strauss SJ, McTiernan A, Whelan JS: Late relapse of osteosarcoma: implications for follow-up and screening. Pediatr Blood Cancer; 2004 Nov;43(6):692-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Eight patients with osteosarcoma treated at The London Bone and Soft Tissue Tumour Service since 1986 developed recurrence of disease after 5 years, the latest 14 years after the initial diagnosis.
  • Five patients developed pulmonary metastases, two patients isolated bone metastases and one patient intra-abdominal metastases.
  • Although a second complete remission was achieved in six patients, four patients relapsed again, all with pulmonary metastases.
  • Two patients had co-existent brain metastases.
  • One of those with a second recurrence has achieved a further complete remission and remains well 50 months after the most recent treatment.
  • A second patient is disease-free 24 months after complete excision of an isolated pulmonary metastasis and one further patient is disease-free 6 months after chemotherapy and pneumonectomy for pleural and pulmonary metastases.
  • [MeSH-minor] Adolescent. Adult. Female. Follow-Up Studies. Humans. Male. Neoplasm Metastasis. Recurrence. Survival Rate. Time Factors

  • Genetic Alliance. consumer health - Osteosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2004 Wiley-Liss, Inc.
  • (PMID = 15390283.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Ananth S, Amin M: Implantation of oral squamous cell carcinoma at the site of a percutaneous endoscopic gastrostomy: a case report. Br J Oral Maxillofac Surg; 2002 Apr;40(2):125-30
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 55-year-old man had an operation and radiotherapy for a squamous cell carcinoma of the oral cavity and developed a metastatic deposit at the site of a percutaneous endoscopic gastrostomy, with no other evidence of systemic spread.
  • Treatment of the metastasis was by neo-adjuvant chemotherapy with cisplatin and 5-fluorouracil (5-FU) followed by en bloc resection of the stomal recurrence on the anterior abdominal wall.
  • Only 17 other cases of metastasis to this site from a primary tumour in the upper aerodigestive tract have been reported.
  • [MeSH-major] Abdominal Neoplasms / etiology. Abdominal Neoplasms / secondary. Carcinoma, Squamous Cell / secondary. Gastrostomy / adverse effects. Head and Neck Neoplasms / pathology. Intubation, Gastrointestinal / adverse effects. Neoplasm Seeding

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Oral squamous cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12180203.001).
  • [ISSN] 0266-4356
  • [Journal-full-title] The British journal of oral & maxillofacial surgery
  • [ISO-abbreviation] Br J Oral Maxillofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Scotland
  • [Number-of-references] 29
  •  go-up   go-down


27. Zhang H, Kong Y, Zhang H, He X, Zhang HY, Liu C, Xiao M, Xu X: Leiomyosarcoma of the inferior vena cava: case report and treatment of recurrence with repeat surgery. Ann Vasc Surg; 2010 Apr;24(3):417.e5-9
Genetic Alliance. consumer health - Leiomyosarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leiomyosarcoma of the inferior vena cava: case report and treatment of recurrence with repeat surgery.
  • Surgical resection currently remains the best treatment; however, recurrence frequently occurs and the 5-year survival rate is only 31%.
  • The aim of this study is to report a case of IVC leiomyosarcoma and treatment of recurrence with repeat surgery.
  • A 36-year-old woman with a high-grade leiomyosarcoma originating from the infrahepatic IVC underwent an en bloc excision of the tumor.
  • Eleven months after the initial operation, two metastases to the omentum were observed.
  • Since the patient showed no response to adjuvant chemotherapy (i.e., a combination of 5-fluorouracil and gemcitabine), repeat operations were used as the main treatment modality for recurrence.
  • The median time to recurrence was 15 months (range 8-27).
  • The middle and upper IVC segments were involved in the local recurrence, and metastatic lesions occurred in multiple sites including the stomach, omentum, mesentery, left liver, and pelvic cavity.
  • Repeat operations to remove the recurrent and metastatic tumors led to a long-term (at least 7 years) survival, and the patient is still alive.
  • Our results suggest that in the setting of chemotherapy-refractory IVC leiomyosarcoma repeat surgery may be an alternative treatment for recurrence and improve survival time.
  • [MeSH-major] Abdominal Neoplasms / surgery. Digestive System Surgical Procedures. Leiomyosarcoma / surgery. Neoplasm Recurrence, Local. Pelvic Neoplasms / surgery. Vascular Neoplasms / surgery. Vascular Surgical Procedures. Vena Cava, Inferior / surgery
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Chemotherapy, Adjuvant. Drug Resistance, Neoplasm. Female. Humans. Reoperation. Time Factors. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Annals of Vascular Surgery Inc. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20036495.001).
  • [ISSN] 1615-5947
  • [Journal-full-title] Annals of vascular surgery
  • [ISO-abbreviation] Ann Vasc Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Sheng XG, Zhang XL, Fu Z, Li HQ, Li QS, Ma ZF, Li DP, Chen ZY: [Value of positron emission tomography-CT imaging combined with continual detection of CA125 in serum for diagnosis of early asymptomatic recurrence of epithelial ovarian carcinoma]. Zhonghua Fu Chan Ke Za Zhi; 2007 Jul;42(7):460-3
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Value of positron emission tomography-CT imaging combined with continual detection of CA125 in serum for diagnosis of early asymptomatic recurrence of epithelial ovarian carcinoma].
  • OBJECTIVE: To evaluate the value of positron emission tomography (PET)-CT imaging combined with continual detection of CA125 in serum for diagnosis of early recurrent ovarian epithelial carcinoma.
  • METHODS: Twenty six patients received PET-CT imaging, who were all diagnosed as primary epithelial ovarian cancer of stage II - IV and had complete remission after cytoreductive surgery and multiple courses of chemotherapy in Shandong Provincial Cancer Hospital.
  • After a steady period, all patients experienced progressive rising of CA125 values 3 times in 2 months.
  • But no positive lesion was found by CT, or although suspicious positive focus was found, the recurrent and (or) metastatic extent was not definite.
  • (1) Of 26 patients, the value of CA125 was more than 35 kU/L in 17, and in 14 of 17, pelvic or abdominal cavity recurrence was diagnosed by CT and PET-CT, and 4 showed simultaneously distant metastasis on PET-CT.
  • In the remaining 3 patients of which CT findings were negative, 2 had pelvic and abdominal cavity recurrence, and one had bone metastasis on PET-CT.
  • Of 9 patients with progressive rising CA125 levels but the value was less than cut-off (< 35 kU/L), only 3 were found recurrence in pelvic and abdominal cavity by CT; however, all showed at least one suspicious recurrent or metastasis lesion on PET-CT. (2) Of 10 patients who received re-cytoreductive surgery, the value of CA125 was higher than cut-off in 6, and less in 4.
  • Four were diagnosed as recurrence by CT and PET-CT, and 6 were only confirmed by PET-CT with 1 - 5 abnormal metabolic lesions found. (3) In 10 patients who received re-cytoreductive surgery, all suspicious positive lesions identified by CT were proved recurrence or metastasis by pathology, and abnormal metabolic lesions showed by PET-CT were all confirmed to be metastasis by postoperative pathology. (4) After 1 month of re-cytoreductive surgery, the value declined by 3.2 fold in 4 whose CA125 value was less than cut-off; in another 6, the value declined to less than cut-off in 4, and in one after 2 cycles of re-chemotherapy, but the remaining one patient had persistent CA125 values more than cut-off.
  • CONCLUSIONS: PET-CT could reveal recurrence and (or) metastasis which may be missed or could not be confirmed by routine diagnostic methods before clinical presentations.
  • Combined with the continual detection of CA125, a high accuracy of diagnosis can be achieved.
  • [MeSH-major] CA-125 Antigen / blood. Neoplasm Recurrence, Local / diagnosis. Ovarian Neoplasms / diagnosis. Ovary / pathology. Positron-Emission Tomography / methods
  • [MeSH-minor] Adult. Aged. Female. Humans. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Prognosis. Reproducibility of Results. Sensitivity and Specificity. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17961335.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / CA-125 Antigen
  •  go-up   go-down


29. Plaat BE, Hollema H, Molenaar WM, Torn Broers GH, Pijpe J, Mastik MF, Hoekstra HJ, van den Berg E, Scheper RJ, van der Graaf WT: Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: differences in clinical outcome and expression of multidrug resistance proteins. J Clin Oncol; 2000 Sep 15;18(18):3211-20
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: differences in clinical outcome and expression of multidrug resistance proteins.
  • PURPOSE: Several studies have reported clinical behavior and chemotherapy resistance in leiomyosarcomas, but these studies did not differentiate between soft tissue leiomyosarcomas (LMS) and malignant gastrointestinal stromal tumors (GIST).
  • PATIENTS AND METHODS: Clinical outcome was evaluated in 29 patients with a primary deep-seated LMS and 26 patients with a primary malignant GIST.
  • Paraffin-embedded material, available for 26 patients with LMS and 25 with GIST, was used for immunohistochemical detection of P-gp, MRP(1), LRP, and c-kit.
  • Metastases occurred in 16 (59%) of 27 assessable LMS patients and in 10 (56%) of 18 assessable GIST patients.
  • LMS predominantly metastasized to the lungs (14 of 16 patients), whereas GIST tended to spread to the liver (five of 10 patients) and the abdominal cavity (three of 10 patients; P: <.001).
  • CONCLUSION: LMS patients have a better survival than GIST patients, and the metastatic pattern is different.
  • [MeSH-major] ATP-Binding Cassette Transporters / biosynthesis. ATP-Binding Cassette, Sub-Family B, Member 1 / biosynthesis. Drug Resistance, Multiple / physiology. Gastrointestinal Neoplasms / metabolism. Leiomyosarcoma / metabolism. Neoplasm Proteins / biosynthesis. Soft Tissue Neoplasms / metabolism. Vault Ribonucleoprotein Particles / biosynthesis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Drug Resistance, Neoplasm. Female. Gene Expression. Humans. Male. Middle Aged. Multidrug Resistance-Associated Proteins. Proto-Oncogene Proteins c-kit / biosynthesis. Stromal Cells / metabolism. Stromal Cells / pathology. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10986053.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ATP-Binding Cassette Transporters; 0 / ATP-Binding Cassette, Sub-Family B, Member 1; 0 / Multidrug Resistance-Associated Proteins; 0 / Neoplasm Proteins; 0 / Vault Ribonucleoprotein Particles; 0 / major vault protein; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


30. Opitz I, Van der Veen H, Witte N, Braumann C, Mueller JM, Jacobi CA: Instillation of taurolidine/heparin after laparotomy reduces intraperitoneal tumour growth in a colon cancer rat model. Eur Surg Res; 2007;39(3):129-35
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To investigate whether irrigation of the abdominal cavity after laparotomy for caecum resection with taurolidine/heparin or adhesion prophylactic substances reduces intraperitoneal tumour growth or the local recurrence rate in a colon carcinoma rat model.
  • Finally, the total number and total weight of intraperitoneal metastases were determined as well as the adhesion score according to Moreno.
  • Metastatic tissue was examined histologically and immunohistochemically (E-cadherin, CD44, beta(1)-integrin).
  • RESULTS: Taurolidine/heparin significantly reduced not only the total number (3 vs. 11 in the control group) but also the total weight (65 vs. 330 mg) of intraperitoneal metastases in comparison to the control group (p = 0.003 and p = 0.005).
  • E-Cadherin expression in the metastatic tissue of animals treated with taurolidine/heparin was significantly decreased (p = 0.016).
  • [MeSH-major] Adenocarcinoma / drug therapy. Anticoagulants / therapeutic use. Antineoplastic Agents / therapeutic use. Colonic Neoplasms / drug therapy. Heparin / therapeutic use. Neoplasm Recurrence, Local / prevention & control. Taurine / analogs & derivatives. Thiadiazines / therapeutic use
  • [MeSH-minor] Abdominal Neoplasms / drug therapy. Abdominal Neoplasms / pathology. Animals. Immunohistochemistry. Instillation, Drug. Laparotomy. Male. Neoplasm Metastasis / pathology. Neoplasm Metastasis / prevention & control. Rats. Tissue Adhesions / prevention & control

  • MedlinePlus Health Information. consumer health - Blood Thinners.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. Taurine .
  • Hazardous Substances Data Bank. HEPARIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17337889.001).
  • [ISSN] 0014-312X
  • [Journal-full-title] European surgical research. Europäische chirurgische Forschung. Recherches chirurgicales européennes
  • [ISO-abbreviation] Eur Surg Res
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Anticoagulants; 0 / Antineoplastic Agents; 0 / Thiadiazines; 1EQV5MLY3D / Taurine; 8OBZ1M4V3V / taurolidine; 9005-49-6 / Heparin
  •  go-up   go-down






Advertisement